<- Go Home

Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Market Cap

SEK 8.8B

Volume

58.4K

Cash and Equivalents

SEK 315.9M

EBITDA

SEK 120.2M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

SEK 641.7M

Profit Margin

75.05%

52 Week High

SEK 547.00

52 Week Low

SEK 238.20

Dividend

N/A

Price / Book Value

4.21

Price / Earnings

64.55

Price / Tangible Book Value

6.23

Enterprise Value

SEK 8.5B

Enterprise Value / EBITDA

64.39

Operating Income

SEK 97.0M

Return on Equity

6.69%

Return on Assets

2.66

Cash and Short Term Investments

SEK 315.9M

Debt

SEK 29.3M

Equity

SEK 2.1B

Revenue

SEK 855.0M

Unlevered FCF

-SEK 143.2M

Sector

Health Care Equipment and Supplies

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches